For PE-backed platforms, regional health systems, and physician entrepreneurs, acquiring an established IVF practice almost always beats the brutal economics of building from scratch — but only if you buy the right asset.
The fertility clinic industry is one of the most capital-intensive and credentialing-dependent sectors in lower middle market healthcare M&A. Whether you are a private equity platform like US Fertility or CCRM pursuing geographic expansion, a regional health system adding reproductive medicine services, or a physician group seeking to scale, the buy-vs-build question carries enormous financial and operational consequences. Building a de novo fertility clinic requires recruiting a board-certified reproductive endocrinologist into a new market, constructing or retrofitting a CLIA-certified IVF laboratory, achieving SART membership, navigating state corporate practice of medicine laws, and earning patient trust in a highly reputation-driven specialty — all before generating meaningful revenue. Acquiring an established clinic, by contrast, delivers immediate cash flow, an accredited laboratory, existing SART success rate data, trained embryology staff, and an active patient base. In a market growing toward $9 billion domestically with accelerating PE consolidation, speed-to-market and brand credibility are decisive competitive advantages. This analysis gives you the unfiltered framework to make the right call.
Find Fertility Clinic Businesses to AcquireAcquiring an existing SART-member fertility clinic with a qualified reproductive endocrinologist under contract, an accredited in-house IVF laboratory, and a documented patient base delivers immediate revenue, validated outcomes data, and a defensible competitive position. For most strategic buyers operating in the $2M–$5M revenue range, acquisition is the faster, lower-risk path to building a fertility platform.
PE-backed fertility networks seeking geographic expansion, regional health systems adding a reproductive medicine service line, or physician entrepreneurs building a multi-site group practice who need a credentialed platform with immediate patient volume and published SART outcomes.
Building a de novo fertility clinic makes sense only in the narrowest circumstances: when a proven reproductive endocrinologist is already committed, a specific underserved geography presents a clear market gap, and the builder has a 3–5 year runway to absorb losses while SART membership, laboratory accreditation, and referral networks are established. For most acquirers, the build path is slower, riskier, and ultimately more expensive than buying an existing practice.
A board-certified reproductive endocrinologist with an established patient following relocating to a new market, or a well-capitalized PE platform that has exhausted acquirable assets in a high-priority geography and can subsidize a 3–5 year de novo ramp from platform cash flows.
For the vast majority of buyers evaluating the fertility clinic space — PE platforms, health systems, and physician group builders — acquisition is the correct answer. The combination of an immediate revenue stream, a published SART outcome track record, an accredited IVF laboratory, and trained embryology staff represents years of compounded operational value that cannot be replicated quickly. The de novo path is viable only when a committed reproductive endocrinologist is already in hand and the target geography has no acquirable asset. Even then, the capital requirements, recruiting challenges, and 3–5 year ramp to competitive SART credibility make building a distant second choice. Focus your energy on sourcing off-market fertility clinic acquisitions, structuring physician rollover equity to retain the founding RE, and investing in due diligence on laboratory condition and regulatory compliance — that is where deals are won and protected.
Is there a board-certified reproductive endocrinologist already committed to the project who brings an established patient following — and if not, how realistic is recruiting one to a startup in your target market?
Are there acquirable SART-member fertility clinics with minimum $1.5M EBITDA, clean regulatory history, and at least one associate RE in your target geography, or has the market been fully consolidated by PE platforms?
What is your true capital availability — can you sustain 3–5 years of operating losses and $2M–$5M in startup costs if you build, or do your LP commitments or personal capital require cash flow within 12–18 months of deployment?
How important is published SART success rate data to your patient acquisition strategy — and are you prepared to compete without it for 2–3 annual reporting cycles while a de novo clinic establishes its outcome track record?
Have you fully underwritten the post-acquisition physician retention risk in any acquisition target — including employment agreement length, non-compete enforceability, associate RE pipeline, and the financial impact of the founding RE departing within 24 months of close?
Browse Fertility Clinic Businesses For Sale
Skip the build phase — acquire existing customers, revenue, and cash flow from day one.
Fertility clinics with SART membership, in-house IVF laboratories, and minimum $1.5M EBITDA typically trade at 5x–9x EBITDA in the current market. Clinics with multiple board-certified REs, above-average published success rates, diversified payer mix including employer benefit contracts, and modern laboratory infrastructure command the higher end of that range. Single-physician practices with no associate RE or below-average SART data trade at a discount, often 5x–6x, to reflect transition and concentration risk.
Fertility clinics are typically excluded from SBA 7(a) eligibility because they are classified as medical practices under SBA's restrictions on healthcare businesses, particularly those structured under the corporate practice of medicine doctrine. The MSO structures commonly used in fertility acquisitions — where a management company contracts with a physician-owned professional entity — add further structural complexity that conflicts with SBA underwriting requirements. Most fertility acquisitions are financed through a combination of private equity capital, seller financing, and debt from healthcare-specialized lenders.
From project initiation to treating the first IVF cycle, most de novo fertility clinics require 18–30 months. This timeline includes real estate selection and lease negotiation, laboratory design and construction, procurement and installation of embryology equipment including laminar flow hoods, incubators, and cryostorage systems, CLIA certification, SART membership application and approval, physician credentialing, and initial patient acquisition. Compressed timelines are possible with an experienced project team, but 18 months should be considered the optimistic floor.
Physician departure is the single most catastrophic post-acquisition risk. A fertility clinic's revenue is often 70–90% attributable to the founding reproductive endocrinologist's clinical reputation, patient relationships, and referral network. If the founding RE exits within 12–24 months of close without a contracted associate in place, patient volume can decline 40–70% within a single cycle year. Mitigating this risk requires long-term employment agreements with meaningful non-competes, equity rollover or earnout structures that incentivize the physician to stay, and ideally a second board-certified RE already under contract at time of acquisition.
The most common structure for a CPOM-compliant fertility clinic acquisition involves an asset purchase at the management company level combined with a long-term Professional Services Agreement between the acquiring MSO and the physician-owned professional corporation, which retains clinical control as required by state law. The founding physician typically retains 20–40% equity through a rollover and receives an earnout tied to patient volume and EBITDA growth over 3–5 years. A seller-financed note representing 10–20% of the purchase price held for 2–3 years, contingent on patient retention milestones, provides further downside protection for the buyer.
Every ART clinic performing IVF in the United States is required by federal law under the Fertility Clinic Success Rate and Certification Act to report annual cycle outcomes to the CDC, which then publishes clinic-specific success rates through the SART database. Buyers must review the last three years of CDC ART reports and SART published data as part of due diligence, benchmarking the clinic's live birth rates per cycle against national and age-stratified averages. Below-average or inconsistently reported outcomes signal laboratory quality issues or patient selection practices that can impair post-acquisition revenue. Any gaps in reporting history or adverse findings should be investigated before close.
More Fertility Clinic Guides
Get access to acquisition targets with real revenue, real customers, and real cash flow.
Create your free accountNo credit card required
For Buyers
For Sellers